文献速递冠心病外科

氯吡格雷与替格瑞洛在非体外循环冠状动脉旁路移植术后的随机试验

A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
PubMed 文献 · Ann Thorac Surg · 2022-11-14

该随机试验纳入278例非体外循环冠状动脉旁路移植术后存在氯吡格雷抵抗的患者,比较阿司匹林联合替格瑞洛(AT组,n=102)与阿司匹林联合氯吡格雷(AC组,n=102)的效果。结果显示两组桥血管闭塞率、心血管死亡、心肌梗死及大出血无显著差异,但AT组主要不良心血管事件发生率较低(HR 0.77,95%CI 0.684-0.891,P=0.01)。作者认为替格瑞洛可能降低氯吡格雷抵抗患者术后MACEs。

要点

  • 氯吡格雷抵抗发生率为18.9%(278/1739),研究排除阿司匹林共抵抗者74例。
  • AT组与AC组桥血管闭塞率分别为3.9%和5.9%(P=0.52),无显著差异。
  • AT组MACEs风险较低(HR 0.77,95%CI 0.684-0.891,P=0.01)。

核心结论

  • 结果表明,替格瑞洛可能降低非体外循环冠状动脉旁路移植术后氯吡格雷抵抗患者的主要不良心血管事件。

研究设计与样本

  • 随机对照试验,2014年11月至2020年11月共1739例患者接受非体外循环冠状动脉旁路移植术,术后第7至9天评估氯吡格雷抵抗,278例(18.9%)存在抵抗(血小板反应单位>208)并入组。
  • 主要终点为桥血管通畅率和主要不良心血管事件(MACEs,定义为术后1年心血管死亡、心肌梗死和再次血运重建的复合终点),共同主要终点为桥血管通畅率,采用意向性治疗分析。

主要发现

  • AT组与AC组桥血管闭塞率分别为3.9%和5.9%(P=0.52),无显著差异。
  • 心血管原因死亡:AT组1.0% vs AC组2.9%(P=0.32),无显著差异;心肌梗死:AT组1.0% vs AC组3.9%(P=0.18),无显著差异。
  • 大出血发生率两组无显著差异(P=0.75)。
  • AT组主要不良心血管事件发生率低于AC组(风险比0.77;95%CI 0.684-0.891;P=0.01)。

临床怎么用

  • 作者认为,替格瑞洛可能与非体外循环冠状动脉旁路移植术后氯吡格雷抵抗患者主要不良心血管事件减少相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to compare the outcomes of aspirin in combination with either ticagrelor or clopidogrel after off-pump coronary artery bypass (OPCAB) in patients with clopidogrel resistance. METHODS: Between November 2014 and November 2020, 1739 patients underwent OPCAB. Aspirin and clopidogrel treatment was initiated the day after surgery. On postoperative days 7 to 9, clopidogrel resistance was evaluated using a point-of-care assay. A total of 278 (18.9%) patients had clopidogrel resistance ( platelet reaction unit >208) and were enrolled in the study. The study investigators excluded patients with coresistance to aspirin (n = 74) and divided the remaining patients (mean age, 67.4 ± 8.5 years) into 2 groups (an aspirin and ticagrelor group [AT group; n = 102] and an aspirin and clopidogrel group [AC group; n = 102]), randomly assigned using a 1:1 ratio block table. The primary end point was graft patency and major adverse cardiovascular events (MACEs; defined as the composite of cardiovascular mortality, myocardial infarction, and repeat revascularization at 1 year after OPCAB), and the coprimary end point was the graft patency rate. The data were analyzed using the intent-to-treat method. RESULTS: The graft occlusion rates in the AT and AC groups were 3.9% and 5.9%, respectively (P = .52). Neither death from cardiovascular causes (1.0% vs 2.9%; P = .32) nor myocardial infarction showed significant differences (1.0% vs 3.9%; P = .18). No significant difference in the rates of major bleeding were found between the 2 groups (P = .75). However, the AT group was associated with a lower rate of MACEs after OPCAB (hazard ratio, 0.77; 95% CI, 0.684-0.891; P = .01). CONCLUSIONS: These results suggest that ticagrelor may be associated with reducing MACEs in patients with clopidogrel resistance after OPCAB.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kim HH, Yoo KJ, Youn YN, et al. A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass. Ann Thorac Surg. 2022. PMID: 36395875. doi:10.1016/j.athoracsur.2022.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。